Empagliflozin in ESKD - A Feasibility Study

NCT05687058 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Kidney Failure, Chronic
Heart Failure

Interventions

DRUG: Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing
DRUG: Empagliflozin 10 mg daily dosing

Sponsor

University of Mississippi Medical Center